News
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...
Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...
The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...
Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...
The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...
TipRanks on MSN1d
GSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer TreatmentGlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
James Schneider, a Goldman (GS) analyst, acknowledged that investor expectations were already “high”, but argued that Nvidia ...
In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback